Imbruvica/Venclyxto tops Gazyva plus chemo in first-line CLL/SLL
Imbruvica treatment regimen demonstrated superior progression-free survival compared to Gazyva combo
Read More
Tag: CLL
NICE backs AZ’ Calquence for chronic lymphocytic leukaemia
The recommendations are positive for a select population of patients with CLL
Read More
Two medicines accepted for use by NHS Scotland
Medicines for blood cancer and a rare muscle disorder will be made available for NHS patients
Read More
EU expands scope of Imbruvica to include untreated CLL patients
Treatment naïve patients lived longer without disease progression with the Imbruvica-based regimen than those given a chemotherapy-based one
Read More
AbbVie’s Venclyxto shows promise as AML treatment
The drug is already on the market to treat chronic lymphocytic leukaemia (CLL)
Read More
AZ’ Calquence boosts PFS in CLL patients
The drug demonstrates “remarkable efficacy”, says AZ’ José Baselga
Read More
AZ’ Calquence shows PFS benefit in CLL patients
A new filing for the drug as a treatment for relapsed or refractory chronic lymphocytic leukaemia is expected later this year
Read More
Green light for Roche/AbbVie’s chemo-free CLL treatment combo
Roche says a combination of Venclyxto and MabThera has been approved in the European Union for people with previously treated chronic lymphocytic leukaemia.
Read More
AbbVie’s Venclyxto hit with NICE rejection
Draft guidelines do not recommend NHS use of AbbVie’s Venclyxto for treating relapsed or refractory chronic lymphocytic leukaemia (CLL).
Read More
Roche’s Venclexta filed in the US for acute myeloid leukemia
Roche group Genentech has filed an application to market Venclexta in the US for acute myeloid leukemia (AML).
Read More
AbbVie unveils high undetectable disease rates for venetoclax/rituximab combo
AbbVie has unveiled new data showing high and durable undetectable minimal residual disease rates in patients with chronic lymphocytic leukaemia treated with venetoclax in combination with rituximab.
Read More
US nod for Venclexta/Rituxan combo
US regulators have approved a combination of AbbVie and Roche’s Venclexta in combination with Roche/Biogen’s Rituxan (rituximab) to treat chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
